Prognostic significance of the immunohistochemical expression of O6‐methylguanine‐DNA methyltransferase, P‐glycoprotein, and multidrug resistance protein‐1 in glioblastomas
- 15 July 2009
- journal article
- research article
- Published by Wiley in Neuropathology
- Vol. 29 (4) , 379-388
- https://doi.org/10.1111/j.1440-1789.2008.00983.x
Abstract
We studied the expression of O6‐methylguanine‐DNA methyltransferase (O6‐MGMT), P‐glycoprotein (Pgp), and multidrug resistance protein‐1 (MRP‐1) in 23 glioblastomas using RT‐PCR, methylation‐specific PCR, and immunohistochemistry, and analyzed their association with overall patient survival. Univariate analysis of collected data demonstrated that the expressions of O6‐MGMT and MRP‐1 detected by immunohistochemistry, in addition to the consistent factors, including preoperative Karnofsky performance scale (KPS), radical surgery, and tumor location and extension, were significant prognostic factors for the overall survival (OS) of patients with glioblastoma, who received nimustine (ACNU)‐based chemotherapy in association with surgery and radiotherapy. Among them, following multivariate analysis, preoperative KPS, radical surgery, tumor location, and the expression of O6‐MGMT remained as significant prognostic factors. These findings suggest that immunohistochemical analysis of O6‐MGMT in patients with glioblastoma can be a useful method to predict the effects of chemotherapy and identify alternative chemotherapeutic regimens for O6‐MGMT‐positive patients.Keywords
This publication has 16 references indexed in Scilit:
- The combined effects of multiple chemotherapeutic agents for malignant glioma cellsJournal of Neuro-Oncology, 2007
- Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patientsActa Neurochirurgica, 2007
- MGMT prognostic impact on glioblastoma is dependent on therapeutic modalitiesJournal of Neuro-Oncology, 2007
- Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomasJournal of Neuro-Oncology, 2004
- O6-methylguanine-DNA methyltransferase methylation andTP53 mutation in malignant astrocytomas and their relationships with clinical courseInternational Journal of Cancer, 2004
- Correlation of Clinical Features and Methylation Status of MGMT Gene Promoter in GlioblastomasJournal of Neuro-Oncology, 2004
- Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with TemozolomideClinical Cancer Research, 2004
- Correlation between Promoter Hypermethylation of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene and Prognosis in Patients with High-grade Astrocytic Tumors Treated with Surgery, Radiotherapy, and 1-(4-Amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based ChemotherapyNeurosurgery, 2004
- Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase π in glioblastoma and the survival of the patients treated with nimustine hydrochloride: An immunohistochemical analysisNeurological Research, 2003
- The Prognostic Value of Tumor Markers in Patients with Glioblastoma Multiforme: Analysis of 32 Patients and Review of the LiteratureJournal of Neuro-Oncology, 2001